DANCHURCHAID
A coalition of international climate organizations will come together for an event in Copenhagen on the 20 March 2024 to deliver recommendations on integrating climate and development for climate finance to world leaders, ahead of a year of intense negotiations, starting at the Copenhagen Climate Ministerial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318208761/en/
Photo: Mathilde Utzon
The year 2024 is of paramount importance for our future. We face an urgent need to handle the climate crisis, within the broader range of Sustainable Development Goals. This year’s high-level meetings leading up to COP29 will focus on climate finance, aiming to address the substantial funding gaps.
To kick-start these discussions DanChurchAid, E3G, the International Institute for Environment and Development, CONCITO, NDC Partnerships, and the UN Foundation are coming together to co-host the virtual and in-person event ‘Integrating Climate and Development for Adaptation Finance’ in Copenhagen on the 20 March, to provide inspiration for the Copenhagen Climate Summit.
“Adaptation finance must be at the heart of the negotiations towards COP29. Adaptation to the consequences of climate change is a question of survival. We need to adapt to a new reality, where droughts, rising sea levels, and heatwaves are becoming increasingly commonplace,” said Secretary General of DanChurchAid, Jonas Nøddekær.
“The countries most vulnerable to climate change have been clear about what they need to adapt to it - more money, on fairer terms and channelled to local people who are best placed to use it. Governments meeting in Copenhagen have a chance to put down a marker for stronger climate outcomes later this year and to show they're taking lower-income nations seriously,” said Ebony Holland, IIED’s nature-climate policy lead.
“The decisions that governments make this year will shape if, how, and how much finance is delivered over the next decade and beyond. We need to make sure that finance is adequate to achieve the Sustainable Development Goals and a climate resilient future for all,” said Cristina Rumbaitis del Rio, Senior Advisor, Adaptation and Resilience, UN Foundation.
“We must be striving for our climate and development goals concurrently and linking the two. For developing countries, adaptation and resilience are both a priority and a tremendous challenge. The NDC Partnership supports countries efforts to raise ambition in ways that are implementable, financeable and help foster more equitable and sustainable development, through effective coordinated support of more than 220 members,” said Pablo Vieira, Global Director of the NDC Partnership.
“Globally, all stakeholders must come together behind a coherent framework for climate finance as presented by the Independent High-Level Group on Climate Finance to massively upscale funding for integrated climate and development action. Country owned climate plans (NDCs) that integrate adaptation and long-term development plans must be turned into investment plans by 2030,” said Chairperson of the Board of CONCITO, Connie Hedegaard.
“The climate and development ministerials have shone a light on the reforms needed to how we do adaptation finance to shift towards more systemic resilience investments. Denmark, Samoa and their co-champions of the adaptation finance vision agreed at last year’s ministerial have a chance to drive a scale up and improvement in adaptation finance over the next couple of years as countries prepare their next climate policy updates,” said Alex Scott, Climate Diplomacy and Geopolitics Programme Lead at E3G
Event details and registration: The event will take place on the 20 March 2024, from 14:00-16:30, at:
DanChurchAid, Meldahlsgade 3, 1613 Copenhagen V, Denmark.
For registration for either online or in-person participation, please send an email to copenhagenevent@dca.dk
For media request please contact Mattias Söderberg, at: msd@dca.dk or +45 29700609.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318208761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
